NAFARELIN IN THE TREATMENT OF ENDOMETRIOSIS - DOSE MANAGEMENT

Authors
HULL ME BARBIERI RL
Citation
Me. Hull et Rl. Barbieri, NAFARELIN IN THE TREATMENT OF ENDOMETRIOSIS - DOSE MANAGEMENT, Gynecologic and obstetric investigation, 37(4), 1994, pp. 263-264
Citations number
7
Categorie Soggetti
Obsetric & Gynecology
Journal title
Gynecologic and obstetric investigation → ACNP
ISSN journal
03787346
Volume
37
Issue
4
Year of publication
1994
Pages
263 - 264
Database
ISI
SICI code
0378-7346(1994)37:4<263:NITTOE>2.0.ZU;2-2
Abstract
Nafarelin, a gonadotropin-releasing hormone agonist, has been shown to be effective in the treatment of endometriosis. The standard dosage i s 200 mu g bid intranasally. Side effects most commonly include those associated with estrogen deprivation. By assessing estrogen status, th e standard dosage can be manipulated to minimize these side effects an d increase patient compliance.